Brain delivery of thyrotropin-releasing hormone via a novel prodrug approach

Katalin Prokai-Tatrai, Daniel L. De La Cruz, Vien Nguyen, Benjamin P. Ross, Istvan Toth, Laszlo Prokai

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Using thyrotropin-releasing hormone (TRH) as a model, we explored whether synergistic combination of lipoamino acid(s) and a linker cleaved by prolyl oligopeptidase (POP) can be used as a promoiety for prodrug design for the preferential brain delivery of the peptide. A representative prodrug based on this design principle was synthesized, and its membrane affinity and in vitro metabolic stability, with or without the presence of a POP inhibitor, were studied. The in vivo formation of TRH from the prodrug construct was probed by utilizing the antidepressant effect of the peptide, as well as its ability to increase acetylcholine (ACh) synthesis and release. We found that the prototype prodrug showed excellent membrane affinity and greatly increased metabolic stability in mouse blood and brain homogenate compared to the parent peptide, yet a POP inhibitor completely prevented prodrug metabolism in brain homogenate. In vivo, administration of the prodrug triggered antidepressant-like effect, and microdialysis sampling showed greatly increased ACh release that was also antagonized upon a POP inhibitor treatment. Altogether, the obtained promising exploratory data warrant further investigations on the utility of the prodrug approach introduced here for brain-enhanced delivery of small peptides with neurotherapeutic potential.

Original languageEnglish
Article number349
Issue number7
StatePublished - Jul 2019


  • Brain-targeting prodrug design
  • Cns-drug delivery
  • Lipoamino acid
  • Prolyl oligopeptides (POP)
  • Trh


Dive into the research topics of 'Brain delivery of thyrotropin-releasing hormone via a novel prodrug approach'. Together they form a unique fingerprint.

Cite this